The Impact of Gut Microbiota on Liver Diseases: Insights into Pathophysiology, Diagnosis, and Emerging Therapeutic Approaches
Main Article Content
Abstract
The gut microbiota plays a pivotal role in maintaining metabolic homeostasis and immune regulation, with its dysregulation increasingly recognized as a critical factor in the pathogenesis of liver diseases. This review explores the intricate interplay between gut microbial composition and liver health, focusing on the gut-liver axis as a key mediator. The disruption of gut barrier integrity and subsequent translocation of microbial products, such as lipopolysaccharides and short-chain fatty acids, contribute to the progression of liver disorders, including non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), and cirrhosis. The review also examines the implications of microbial dysbiosis in liver inflammation, fibrosis, and hepatocarcinogenesis, highlighting the diagnostic potential of microbiota profiling and biomarkers. Finally, emerging therapeutic strategies, such as probiotics, prebiotics, fecal microbiota transplantation, and precision microbiome editing, are discussed as promising avenues for intervention. Understanding the bidirectional relationship between the gut microbiota and the liver offers novel insights into disease mechanisms and opens the door for innovative therapeutic approaches in hepatology.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Xiao J., Wang F., Wong N.-K., et al. Global liver disease burdens and research trends: analysis from a Chinese perspective. Journal of Hepatology. 2019;71(1):212–221.
doi: 10.1016/j.jhep.2019.03.004.
II. Verma M., Kulshrestha S., Puri A. Genome sequencing. Methods in Molecular Biology. 2017;1525:3–33. doi: 10.1007/978-1-4939-6622-6_1.
III. Ji F., Sadreyev R. I. RNA-seq: basic bioinformatics analysis. Current Protocols in Molecular Biology. 2018;124(1):p. e68. doi: 10.1002/cpmb.68.
IV. Milosevic I., Vujovic A., Barac A., et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. International Journal of Molecular Sciences. 2019;20(2):p. 395. doi: 10.3390/ijms20020395.
V. Acharya C., Bajaj J. S. Gut microbiota and complications of liver disease. Gastroenterology Clinics of North America. 2017;46(1):155–169.
doi: 10.1016/j.gtc.2016.09.013.
VI. Acharya C., Sahingur S. E., Bajaj J. S. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight. 2017;2(19)
doi: 10.1172/jci.insight.94416.e94416
VII. Bajaj J. S. Alcohol, liver disease and the gut microbiota. Nature Reviews Gastroenterology & Hepatology. 2019;16(4):235–246.
doi: 10.1038/s41575-018-0099-1.
VIII. Dubinkina V. B., Tyakht A. V., Odintsova V. Y., et al. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. Microbiome. 2017;5(1):p. 141.
doi: 10.1186/s40168-017-0359-2.
IX. Safari Z., Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD) Cellular and Molecular Life Sciences. 2019;76(8):1541–1558.
doi: 10.1007/s00018-019-03011-w.
X. Wang J., Wong Y.-K., Liao F. What has traditional Chinese medicine delivered for modern medicine? Expert Reviews in Molecular Medicine. 2018;20:p. e4. doi: 10.1017/erm.2018.3.
XI. Wang W.-J., Zhang T. Integration of traditional Chinese medicine and western medicine in the era of precision medicine. Journal of Integrative Medicine. 2017;15(1):1–7.doi:10.1016/s2095-4964(17)60314-5.
XII. .Xie Y., Hu F., Xiang D., et al. The metabolic effect of gut microbiota on drugs. Drug Metabolism Reviews. 2020;52(1):139–156.
doi: 10.1080/03602532.2020.1718691.
XIII. Feng W., Ao H., Peng C., Yan D. Gut microbiota, a new frontier to understand traditional Chinese medicines. Pharmacological Research. 2019;142:176–191. doi: 10.1016/j.phrs.2019.02.024.